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Abstract
Background: Advanced endometrial cancer often shows resistance to clinical chemotherapy although potencies of
anticancer drugs in vitro are promising. The disparity suggests that in vivo microenvironments are not recapitulated
by in vitro models used for preclinical testing. However, spheroids replicate some important properties of tumours
in vivo. Therefore, for the first time, we compared effects of doxorubicin and cisplatin on 3D multicellular structures
and 2D cell monolayers of endometrial cancer cells.
Methods: 3D multicellular structures were generated by culturing cancer cells on non-adherent surfaces; and for
comparison cell monolayers were cultured on adherent culture plates. Ishikawa, RL95-2, and KLE cell lines were
studied. Morphologies of 3D multicellular structures were examined. After 48 hours treatment with anticancer
drugs, apoptosis, proliferation, glucose metabolism and vascular endothelial growth factor (VEGF) were analysed.
Immunostaining of PCNA, Glut-1, p-Erk1/2, SOD-1 and p-Akt1/2/3 was also performed.
Results: Distinct 3D multicellular morphologies were formed by three different endometrial cancer cell lines.
Doxorubicin induced less apoptosis in 3D multicellular structures of high grade cancer cells (RL95-2 and KLE cell lines)
than in cell monolayers. Parallel alterations in Erk1/2 phosphorylation and cell proliferation might suggest they were
linked and again doxorubicin had less effect on 3D multicellular structures than cell monolayers. On the other hand,
there was no correlation between altered glucose metabolism and proliferation. The responses depended on cancer
cell lines and were apparently not mediated by altered Glut-1 levels. The level of SOD-1 was high in 3D cell cultures.
The effects on VEGF secretion were various and cancer cell line dependent. Importantly, both doxorubicin and cisplatin
had selective paradoxical stimulatory effects on VEGF secretion. The microenvironment within 3D multicellular
structures sustained Akt phosphorylation, consistent with it having a role in anchorage-independent pathways.
Conclusions: The cancer cells responded to microenvironments in a distinctive manner. 3D multicellular structures
exhibited greater resistance to the agents than 2D monolayers, and the differences between the culture formats
were dependent on cancer cell lines. The effects of anticancer drugs on the intracellular mediators were not similar
in 3D and 2D cultures. Therefore, using 3D cell models may have a significant impact on conclusions derived from
screening drugs for endometrial carcinomas.
Background
Endometrial carcinoma is the most common gynaecolo-
gic malignancy in developed countries [1-3]. The early
stage of disease is highly curable with a 5-year survival
rate of more than 80% [4]. However, advanced disease
h a sl o ws u r v i v a lr a t e so fl e s st h a n2 0 % ,a n dm e t a s t a t i c
appearance is a significant cause of mortality [5].
Chemotherapeutic regimens for endometrial cancer
include doxorubicin and cisplatin. Doxorubicin increases
cell death through multiples pathways [6]. Cisplatin is a
platinum-based drug and is believed to affect prolifera-
tion and apoptosis [7,8]. Only 20-25% of patients
respond to these agents suggesting the efficacy of che-
motherapy in the clinic is less effective than results
obtained from evaluation of in vitro 2D cell culture
models [9]. Therefore, a cell model, which represents
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for studying endometrial cancer.
In recent years, 3D multicellular structures, sometimes
called spheroids, have gained attention for their use in
screening novel anticancer drugs. Numerous experimen-
tal data in vitro have suggested that spheroids represent
physiological tumours better than cell monolayers
[10,11]. The behaviour and growth of cancer cells in
spheroids have been studied to a limited extent for
some solid tumours including breast, colon, prostate,
and ovarian tumours but not at all for endometrial can-
cer [12-16]. Spheroids of cancer cells are potentially
valuable cell models for studying tumour growth and
development prior to establishment of angiogenesis and
during the metastatic process [14]. Spheroids are com-
posed of heterogeneous cancer cell populations that
have distinct energy and nutrient metabolism, and com-
plex cell-cell and cell-extracellular matrix interactions
[10,11,17]. The responses of anticancer agents in spher-
oids may more closely reflect the true efficacy of agents
observed in clinical settings.
The advantages of using multicellular structures over
cell monolayers have been suggested. However, there is
no data on the use of multicellular structures for study-
ing the behaviour of endometrial cancer. We hypothe-
sised that multicellular structures of endometrial cancer
might exhibit greater resistance to doxorubicin and cis-
platin than cell monolayers and portray the in vivo
response more accurately. Therefore, the purpose of this
work was, for the first time, to investigate and compare
antitumour activities of doxorubicin and cisplatin in
multicellular structures and cell monolayers of endome-
t r i a lc a n c e rc e l ll i n e s .I nt h i ss t u d y ,w eu s e‘spheroid’ to
mean a multicellular structure that has a compact struc-
ture and the diameter is greater than 100 μm. The end-
point analysis after drug treatments included apoptosis,
proliferation markers, glucose metabolism markers,
endogenous antioxidant protein, vascular endothelial
growth factor (VEGF) secretion and expression of the
intracellular mediators, Akt, Erk and their phosphory-
lated forms. Some of these biomarkers are used in the
clinical prognostic evaluation after anticancer drug
treatment.
Materials and methods
Cell lines and reagents
Endometrial cancer cell lines Ishikawa (grade 1 with
PTEN and p53 mutations) was gifted by Dr Masato
Nishida, Kasumigaura National Hospital, Tsuchiura-shi,
Ibaraki-ken, Japan. RL95-2 (grade 2, with PTEN and p53
mutations) was purchased from ATCC. KLE (grade 3,
with wild type PTEN but p53 mutation), was gifted by
Professor Eric Asselin, University of Quebec at Trois-
Rivieres, Quebec, Canada. Ishikawa and RL95-2 cells
were maintained in MEM medium (GIBCO
®,I n v i t r o -
gen, New Zealand) supplemented with 10% fetal bovine
serum (FBS), 500 units/ml of penicillin/streptomycin
and 1 mM glutamax. KLE cells were maintained in
DMEF-F12 medium (GIBCO
®, Invitrogen) supplemen-
ted with 10% FBS, 500 units/ml of penicillin/streptomy-
cin and 1 mM glutamax. Doxorubicin, cisplatin,
bromodeoxyuridine (BrdU) and propidium iodide (PI)
were purchased from Sigma-Aldrich (New Zealand).
Antibodies (Erk1/2, BrdU, p-ERK1/2, Akt, p-Akt (Ser-
473), GAPDH, SOD1, b-actin, b1-integrin, anti-Mouse
IgG-HRP, and anti-Rabbit IgG-HRP) were purchased
from Santa Cruz Biotechnology (CA, USA).
Cell culture
Generation of multicellular structures: twenty-four well
culture plates were coated with poly-HEMA at 37°C
overnight with continuous shaking. Prior to cell culture,
culture well plates were washed once with PBS pH 7.4.
The cells were plated in 24-well plates at a density of
100,000 cells/well. For monitoring the growth of cells in
3D multicellular structures, cells were collected and
incubated with trypsin-EDTA for 10-20 minutes prior to
counting them with a haemocytometer. For cell mono-
layers, cells were plated at a density 100,000 of cells/
well. Cells were incubated at 37°C in a humidified 5%
CO2 atmosphere for 5 days.
Determination the compactness of a 3D
multicellular structure
After 5 days of culture, spheroids, cell aggregates and
cell clusters were incubated with trypsin-EDTA for 7
minutes and triturated with 1 ml pipette. The enzymatic
reaction was then terminated by addition of PBS. Differ-
ential interface contrast (DIC) images were captured
with epifluorescence microscopy (AxioVision 4.5. Apo-
tome software, Carl Zeiss, Oberkochen, Germany).
Treatment with clinical drugs
After 5 days culturing, the supernatants were replaced
with 1 ml fresh medium. Agents were added to cells
and incubated for a further 48 hours. Doxorubicin and
cisplatin were dissolved in 100% DMSO, and a similar
amount of DMSO was added in the control.
Detection of cell apoptosis using
Annexin-V/Propidium iodide (PI)
After treatment with potential agents, cells were har-
vested, trypsinised, washed and centrifuged. Cell pellets
were resuspended in binding assay buffer and annexin-V
conjugated FITC solution (Invitrogen, New Zealand)
was added. Cells were then incubated in the dark at
room temperature for 20 minutes. Propidium iodide (PI)
was then added at final concentration of 10 μg/ml.
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man Coulter). Data were collected from at least four
independent experiments and were then analysed with
CXP Software (Beckman Coulter).
Measurement of cell proliferation by BrdU incorporation
After cells were treated with agents, BrdU at final con-
centration at 20 μM was added and incubated for a
further 5 hours at 37°C in a 5% CO2 atmosphere. Cells
were harvested, trypsinised and fixed with 4% parafor-
maldehyde in PBS pH 7.4 and then washed with PBS
pH 7.4. Cells were permeabilised with 0.1% Triton X-
100 for 20 minutes and washed. Cells were incubated
with anti-BrdU antibody overnight at 4°C, washed and
stained with anti-mouse IgG-FITC for 60 minutes and
further incubated with 10 μg/ml PI for 20 minutes. Cells
were then analysed by FACS (Beckman Coulter) and
data were collected from at least four independent
experiments and were then analysed with CXP Software,
Beckman Coulter).
Measurement of glucose metabolism by uptake of 2-[N-
(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]-2-deoxy-D-
glucose (2-NBDG)
Multicellular structures were washed once with PBS pH
7.4 and then were suspended in 1 ml assay buffer and
2-NBDG was added at 20 μM final concentrations. Cells
were incubated at 37°C in a humidified 5% CO2 atmo-
sphere for 60 minutes and were washed with ice cold
PBS pH 7.4 and were trypsinised. Cell suspensions were
kept in cold assay buffer and 2-NBDG stained cells were
analysed with FACS (Beckman Coulter) and data were
collected from at least four independent experiments
and were then analysed with CXP Software (Beckman
Coulter). For cell monolayers, cells were first trypsinised
prior to incubation with 2-NBDG.
Indirect immunofluorescent analysis
Multicellular structures were fixed with 4% paraformal-
dehyde in PBS pH 7.4 for 40 minutes. The 3D multicel-
lular structures were washed and embedded in mixtures
of OTC: PBS pH 7.4 (70%:30%). Frozen sections were
cut 7 μm thick and placed on polylysine coated slides.
The sections were blocked with 5% BSA in PBS pH 7.4
for 60 minutes and were washed with PBS pH 7.4. The
cut sections were incubated with -20°C methanol (99%)
for 10 minutes and washed with ice cold PBS pH 7.4
and then incubated with a 1/200 dilution of primary
antibodies overnight at 4°C. The sections were then
washed and incubated with a 1/500 dilution of second-
ary Alexa™ 488- or FITC-conjugated antibodies at 37°C
for 60 minutes. The sections were stained with 10 μg/ml
Hoechst (Molecular Probe, Invitrogen) at 37°C for 20
minutes. The sections were washed extensively with ice
cold PBS pH 7.4 plus 0.05% Tween-20. Anti-fading
(Dako Florescent Mounting Medium) was added and
sections were analysed with epifluorescence microscopy
(AxioVision 4.5. Apotome software, Carl Zeiss, Oberko-
chen, Germany). Fluorescent images were collected from
at least two independent experiments and at least 7
images from each experiment were captured and
analysed.
Immunoblotting analysis
Multicellular structures and adherent cells were lysed
with cold RIPA buffer containing protease inhibitor
cocktail tablets (Complete Mini, Roche, New Zealand)
on ice for 30 minutes. Sample buffer was added and
protein lysate was boiled at 95°C for 5 minutes. Cells
were centrifuged at 14,000 rpm at 4°C for 10 minutes.
Proteins were loaded and separated with SDS-PAGE
using 5% stacking and 7.5-10% separating gels. Proteins
were then electro-transferred onto PVDF membranes
(100 Voltage, 60 minutes). The membrane was blocked
with 5% non-fat milk powder in TBS-T buffer for 60
minutes. Membranes were then washed and incubated
with primary antibodies over night at 4°C. Membranes
were washed with TBS-T, incubated with a secondary
peroxidase-conjugated antibody for 90 minutes and
washed. Antibody localisation was determined using an
enhanced chemiluminescent detection system ECL
(Amersham, GE Healthcare). To ensure equal protein
loading GAPDH and beta-actin proteins were used as a
house keeping protein. Cell lysate from at least four
independent experiments were collected and analysed
for western blotting. Protein bands were detected and
analysed by using Alliance 4.7, Unitec (Cambridge, UK).
ELISA of vascular endothelial growth factor (VEGF)
ELISA of VEGF was performed using the DuoSet
Human VEGF ELISA Kit (R&D System) that detects
VEGF-A isoforms. Cell media from at least four inde-
pendent experiments were collected and analysed for
VEGF.
Statistical analysis
Statistics were performed using SigmaPlot 11. Data were
statistically analysed using Student’s t-test and ANOVA
and P < 0.05 was considered significant. All data are
presented as mean ± SEM.
Results
Different subtypes of endometrial cancer generated
distinct morphologies of spheroids
After 24 hours of culturing, small aggregations of cells
were observed (data not shown), and larger multicellular
structures formed after 5 days of culture (Figure 1A).
Ishikawa cells formed large, tightly compact spheroids,
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100 μm. The compact spheroids were resistant to the
enzymatic treatment of trypsin-EDTA. On the other
hand, RL95-2 cells tended to form loose multicellular
aggregates, which were easily dissociated by trypsin-
EDTA digestion. KLE cells tended to develop small cell
clusters that were dissociated into single cells after tryp-
sin-EDTA treatment. The average diameter of 3D multi-
cellular structures of Ishikawa, RL95-2 and KLE cells
before the enzymatic treatment were 168.60 ± 9.18,
135.39 ± 8.5 and 43.72 ± 3.55 μm, respectively. The
growth of multicellular structures was monitored by
counting total cell numbers at intervals of 2 days (Figure
1B). Increasing cell numbers of Ishikawa and RL95-2
cell lines were correlated with increasing time of culture.
However, KLE cell line reached a plateau after 6 days of
culture. The formation of compact spheroids in Ishi-
kawa cell line, cell aggregates in RL95-2 and cell clusters
in KLE cell line was not associated with the expression
of b1-integrin (Figure 1C).
Effects of doxorubicin and cisplatin on viability and
apoptosis
Doxorubicin reduced cell viability of Ishikawa, RL95-2
and KLE cell lines in a dose dependent manner (Figure
2A-a, c, e). However, 3D multicellular structures of
these cell lines had higher viability than their cell mono-
layer counterparts. Cisplatin had limited effects on the
reduction of cell viability of Ishikawa and KLE cell lines
(Figure 2B-b, f) but it slightly decreased the viability of
RL95-2 cell line in the 2D culture (Figure 2B-d).
Next, we determined whether reduction of cell viabi-
lity was due to induction of apoptosis-related cell death.
Doxorubicin increased the percentage of apoptotic cells
in both spheroids and cell monolayers of Ishikawa cells
(Figure 2B). Similarly, doxorubicin strongly induced
apoptosis in RL95-2 cells. However, cell aggregates of
RL95-2 cell line had significantly fewer apoptotic cells
than cell monolayers. Doxorubicin also increased apop-
tosis in both cell clusters and monolayers of KLE cell
line and again cell clusters were less sensitive to doxoru-
bicin than cell monolayers. Cisplatin did not produce an
increase of apoptotic cells in any cell lines. Immuno-
f l u o r e s c e n ti m a g e ss h o w e dd oxorubicin was distributed
throughout 3D multicellular structures of all cancer cell
lines (Figure 2C). This would suggest that drug accessi-
bility does not account for the insensitivity of cells in
multicellular structures to doxorubicin.
Effects on cell proliferation
Noting that doxorubicin and cisplatin had less effect on
apoptosis in 3D multicellular structures than cell mono-
layers, we hypothesised that these agents might, how-
ever, exert strong anti-proliferative effects. To
investigate this, we used BrdU incorporation and stain-
ing of PCNA to analyse cell proliferation. Our results
Figure 1 Morphology, growth pattern, and expression of b1-integrin. (A) Differential interface contrast (DIC) images of 3D multicellular
morphologies from structures formed by epithelial endometrial cancer cell lines after 5 days cultured on poly-HEMA coated cultureware.
Ishikawa cell line formed tightly compact spheroids, which were resistant to trypsin-EDTA digestion. RL95-2 and KLE cell lines formed cell
aggregates and clusters respectively, and they were easily dissociated by trypsin-EDTA treatment. The scale bar is 100 μm. (B) The growth of
Ishikawa, RL95-2 and KLE cell lines cultured in 3D structures. The total cell number was counted by a haemocytometer at intervals of 2 days. The
open circle (○), dark circle (●) and triangle (▼) represent Ishikawa, RL95-2 and KLE cell lines, respectively. (C) The expression of b1-integrin was
observed in Ishikawa, RL95-2 and KLE cell lines.
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Page 4 of 16Figure 2 Cell viability, apoptosis and distribution of doxorubicin (DOX). (A) Cell viability after 48 hours treatment with doxorubicin (DOX)
and cisplatin (CIS). The treated cells were stained with PI and analysed with FACS. The PI positive cell staining was calculated relatively to the
control. The (■) dark and (grey square symbol) grey bars represent multicellular structures and cell monolayers, respectively. (B) After 48 hours
treated with anticancer agents, cells were stained with annexin-FITC and PI and analysed with FACS. Multicellular structures and cell monolayers
of Ishikawa, RL95-2 and KLE cells were studied. The data are presented as mean ± SEM from at least four separate experiments. The (■) dark and
(grey square symbol) grey bars represent 3D multicellular structures and cell monolayers respectively. (*) P < 0.05, compared to control
multicellular structures. (#) P < 0.05, compared to control cell monolayers. (■) P < 0.05, comparison of between 3D cell cultures and cell
monolayers. (C) Distribution of doxorubicin (DOX) within 3D multicellular structures of Ishikawa, RL95-2 and KLE after 48 hr incubations. DOX was
located in the nucleus of cancer cells in multicellular structures. Images were obtained and representative of two independent experiments.
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kawa cells was not affected by the anticancer drugs (Fig-
ure 3A). In contrast, proliferation of cell monolayers
was significantly reduced by both drugs.
Doxorubicin reduced cell proliferation in both cell
aggregates and cell monolayers of RL95-2 cells but cis-
platin did not. Cell clusters of KLE cell line exhibited no
change in cell proliferation after doxorubicin or cisplatin
treatment. It is notable that in cell monolayers of KLE
cell line proliferation was significantly increased after
cisplatin treatment.
Immunohistochemistry of PCNA in frozen sections of
3D multicellular structures was employed to obtain
details on changes in proliferation that might occur in
limited regions. It was revealed that PCNA was localised
at the rim of control spheroids of Ishikawa cell line (Fig-
ure 3B, C). After spheroids were treated with doxorubi-
cin, the staining of PCNA was observed predominantly
around the core of Ishikawa spheroids (Figure 3C). Cis-
platin failed to increase the staining of PCNA in central
regions in distinction from doxorubicin-treated spher-
oids. In contrast to spheroids of Ishikawa cells, the
staining of PCNA in control cell aggregates of RL95-2
cells was predominantly localised adjacent to central
regions. Doxorubicin substantially reduced the staining
of PCNA. Treatment with cisplatin did not markedly
alter the staining of PCNA. There was no observed
change of PCNA staining in KLE cell clusters after
treatment.
Effects on upstream proliferative markers Erk1/2
and p-Erk1/2
The effects of doxorubicin and cisplatin on cell prolif-
eration may be a result of the inactivation of MAPK. To
investigate this, immunohistochemistry of p-Erk1/2 in
the multicellular structure of Ishikawa, RL95-2, and KLE
cells was performed. Cells showed small vesicle-like
staining at the rim and core regions (Figure 4A). How-
ever, after being treated with doxorubicin diffuse stain-
ing was observed in Ishikawa spheroids. Doxorubicin
decreased the staining of p-Erk1/2 in cell aggregates of
RL95-2 cells but did not alter the staining in KLE cell
clusters. Cisplatin did not alter the observed staining of
p-Erk1/2. We next evaluated the expression of total
Erk1/2 and p-Erk1/2 by Western blotting. Spheroids of
Ishikawa cells treated with doxorubicin did not signifi-
cantly reduce the expression of total Erk1/2 (Figures
4B-b, 5A) but doxorubicin reduced p-Erk1/2 in spher-
oids of Ishikawa cells (Figure 5B). Furthermore, doxoru-
bicin significantly reduced both Erk and p-Erk1/2 in cell
monolayers of Ishikawa cells (Figures 4B-c, d, 5A, B).
Interestingly, in doxorubicin treated Ishikawa cells levels
of p-Erk1/2 in spheroids were maintained at substan-
tially higher levels compared to cell monolayers (Figure
5B). The total Erk1/2 in cell aggregates and cell mono-
layers of RL95-2 cell line tended to reduce after doxoru-
bicin treatment but the difference was not statistically
significant (Figures 4B-f, 5h, 5C). However, p-Erk1/2 in
both cell aggregates and monolayers of RL95-2 cells
were significantly reduced after being treated with dox-
orubicin (Figure 4B-e, g, 5D). However, the level of p-
Erk1/2 in cell aggregates was marginally higher than cell
monolayer but it was not statistically significant. Doxor-
ubicin also had a tendency (without statistical signifi-
cance) to reduce total Erk and p-Erk1/2 in spheroids
and cell monolayers of KLE cells (Figure 4B-j, i, l, k, 5E,
F). Cisplatin had limited effects in multicellular struc-
tures and cell monolayers of all cell lines.
Therefore, alteration of cell proliferation may be asso-
ciated with levels of phosphorylation of Erk1/2 but also
it appears to be dependent on the individual cell line.
The results suggest that 3D culture enhanced the levels
of expression.
Effects on Glucose metabolism
Alteration of proliferation in 3D cell cultures and cell
monolayers during drug treatment may also be asso-
ciated with the increase of glucose metabolism in cancer
cells. To test this hypothesis, we utilised the fluorescent
glucose analogue, 2-NBDG, which enters cells via glu-
cose transporter proteins (Gluts) including Glut-1. The
results showed that the uptake of 2-NBDG was varied
among cell lines (Figure 6A). KLE cells showed the
highest activity of 2-NBDG uptake (cell monolayers,
97.04% ± 0.179, cell clusters, 92.75% ± 0.56), followed
by Ishikawa cells (cell monolayers, 81.94% ± 3.64, spher-
oids, 76.76% ± 1.08) and RL95-2 cells (cell monolayers,
72% ± 4.2, cell aggregates, 47.87% ± 0.9). In addition,
cell monolayers had greater uptake of 2-NBDG than cell
clusters and aggregates in KLE and RL95-2 cell lines
respectively (t-test, P < 0.05), but Ishikawa cell line did
not show any difference between cell monolayers and
spheroids.
Interestingly, after treatment with doxorubicin, the
uptake of 2-NBDG in spheroids and cell aggregates of
Ishikawa and RL95-2 cells, respectively, was increased
whereas it was reduced in cell clusters of KLE cells (Fig-
ure 6A). However, there was no change in cell mono-
layers of Ishikawa and RL95-2 cells but there was an
increase of 2-NBDG uptake in KLE cell monolayers.
Cisplatin reduced the uptake of 2-NBDG in cell aggre-
gates of RL95-2 cells and in both cell clusters and
monolayers of KLE cells.
The increased uptake of 2-NBDG may be due to the
upregulation of Glut -1 expression. To investigate this,
we next examined immunofluorescent staining of Glut-
1 protein. In the control spheroid of Ishikawa cells, the
staining was observed predominantly in regions that
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Page 6 of 16Figure 3 The effect of doxorubicin (DOX) and cisplatin (CIS) on cell proliferation. (A) Effects of doxorubicin and cisplatin on cell
proliferation in multicellular structures and cell monolayers. After 48 hours treatment of cells with anticancer agents, BrdU was added to the
cultures for 5 hours. Cells were trypsinised, fixed, permeabilised, exposed to anti-BrdU antibody, stained with anti-mouse conjugated to Alexa™
488 nm and analysed with FACS. The (■) dark and (grey square symbol) grey bars represent multicellular structures and cell monolayers
respectively. (*) P < 0.05, compared to control multicellular structures. (#) P < 0.05, compared to control cell monolayers. The data are presented
as mean ± SEM from at least four separate experiments. (B) Effects on staining patterns of proliferating cell nuclear antigen (PCNA) by
doxorubicin and cisplatin. Frozen sections of multicellular structures were cut, fixed and stained with anti-PCNA antibody. Ishikawa, RL95-2 and
KLE 3D multicellular structures were studied. PCNA is stained green and the nucleus is blue. The scale bar is 50 μm. The images were
representative of at least two separate experiments. (C) Fluorescent intensity profile of PCNA of control and DOX treated Ishikawa spheroids.
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Page 7 of 16Figure 4 Expression of Erk1/2 and p-Erk1/2. (A) Effects on immunohistochemistry staining of active form of Erk (p-Erk) by doxorubicin and
cisplatin. Multicellular structures of Ishikawa, RL95-2 and KLE cells were cut, fixed and stained with anti-p-Erk antibody. p-Erk was stained green
and the nucleus is blue. The scale bar is 50 μm. (B) Western blotting of active form of Erk (p-Erk) and total expression of Erk. After 48 hours
treatment with anticancer drugs, cells were lysed and proteins were separated and analysed by SDS-PAGE and Western blotting. The active form
(p-Erk) and total expression of Erk from multicellular structures of Ishikawa (B:a-b,), RL95-2 (B:e-f), KLE (B:i-j) and cell monolayers of Ishikawa (B:c-d),
RL95-2 (B:g-h), KLE (B:k-l).
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Page 8 of 16were adjacent to the core but the staining was less at
the rim of spheroids (Figure 6B). However, after the
treatment with doxorubicin, strong staining was
observed only at the core. Similarly, control cell aggre-
gates of RL95-2 cells showed strong staining of Glut-1
at the rim and central region but the staining was
reduced after doxorubicin treatment. Doxorubicin
decreased plasma membrane-associated Glut-1 in KLE
spheroids. Interestingly, in spite of cisplatin reducing
the uptake of 2-NBDG by, staining of Glut-1 was not
markedly altered in RL95-2 aggregates and KLE cell
clusters.
Therefore, the effects on proliferation by doxorubicin
and cisplatin were not clearly associated with alteration
of glucose metabolism and that was confirmed by the
pattern of uptake of 2-NBDG and expression of Glut-1.
In addition, the level of glucose metabolism was not
readily associated with the expression of Glut-1.
Figure 5 Densitometry of Erk1/2 and p-Erk1/2. Western blotting analysis of cell protein lysate was from 3D cell cultures and cell monolayers.
GAPDH was used as control for loading. Densitometric analyses were performed using Alliance 4.7, Unitec (Cambridge, UK) and are presented as
a ratio of Erk/GAPDH and pErk/GAPDH. The (■) dark and (grey square symbol) grey bars represent multicellular structures and cell monolayers
respectively. (*) P < 0.05, compared to control multicellular structures. (#) P < 0.05, compared to control cell monolayers. (■) P < 0.05, comparison
of between multicellular structures and cell monolayers. The data are presented as mean ± SEM from at least four separate experiments.
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Page 9 of 16Figure 6 The uptake of 2-NBDG and staining of Glut-1 in multicellular structures and cell monolayers.( A )E f f e c t so nu p t a k eo fa
fluorescent glucose analog 2-NBDG after cells were treated for 48 hours with doxorubicin and cisplatin. The (■) dark and (grey square symbol)
grey bars represent multicellular structures and cell monolayers respectively. (*) P < 0.05, compared to control multicellular structures. (#) P <
0.05, compared to control cell monolayers. Data are expressed as the mean ± SEM from at least four independent experiments. (B) Effects on
immunohistochemistry staining of Glut-1 by doxorubicin and cisplatin. Multicellular structures of Ishikawa, RL95-2, and KLE cells were cut, fixed
and stained with anti-Glut-1 antibody. Glut-1 was stained green and the nucleus is blue. The scale bar is 50 μm.
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treatment
The insensitivity of tumours to cytotoxic agents may be
associated with the elevated expression of endogenous
antioxidant proteins in cancer cells. To examine the
protective role of these antioxidant proteins during drug
exposure in 3D and 2D cell cultures, we selected super-
oxide dismutase-1 (SOD-1) as a surrogate marker for
antioxidant proteins. All cell lines cultured in 3D cell
structures expressed high levels of SOD-1 and its
expression was maintained after the exposure to doxor-
ubicin and cisplatin (Figure 7A). Cell monolayers of
Ishikawa and RL95-2 cell lines decreased SOD-1 expres-
sion after treatment with both drugs. The level of SOD-
1 expression in cell monolayers of KLE did not change.
Effects on secretion of VEGF
Increasing tumourigenic activity is often associated with
elevated secretion of VEGF. Next, we asked whether
doxorubicin and cisplatin inhibits secretion of VEGF.
Therefore, VEGF secreted by 3D cell cultures and cell
monolayers were examined. Cells from 3D cell cultures
generally secreted less VEGF than cell monolayers (Fig-
ure 7B). Spheroids of Ishikawa and cell aggregates of
RL95-2 cells did not change VEGF secretion after dox-
orubicin treatment but it was significantly decreased in
cell monolayers of these cell lines (Figure 7B). Doxoru-
bicin, paradoxically, increased VEGF release from cell
clusters, but not cell monolayers of KLE cells. Cisplatin
also increased VEGF secretionf r o ms p h e r o i d so fI s h i -
kawa cells, but it reduced secretion from monolayers.
Figure 7 Expression of superoxide dismutase-1 (SOD-1) and effects on secretion of vascular endothelial growth factor (VEGF) from
multicellular structures and cells monolayers. (A) Expression of SOD-1 of cells cultured in 3D and 2D cell models. SOD-1 was maintained at
high levels in cancer cells cultured as 3D multicellular structures compared with 2D cell monolayers. (B) Secreted VEGF in the media was
collected and examined by ELISA. The (■) dark and (grey square symbol) grey bars represent 3D cell cultures and cell monolayers respectively.
(*) P < 0.05, compared to control multicellular structures. (#) P < 0.05, compared to control cell monolayers. Data are expressed as the mean ±
SEM.
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from RL95-2 or KLE cells.
Our results suggested doxorubicin and cisplatin selec-
tively altered secretion of VEGF in a manner, which was
dependent on cancer cell line and was also cell culture
method dependent.
Effects on p(Ser473)-Akt after drug treatment
Upregulation of p-Akt may enhance tumour progression
and mediate resistance to drugs [18]. Strong staining of
p-Akt was observed at the cell membrane in the control
of Ishikawa spheroids and RL95-2 cell aggregates (Figure
8A). Doxorubicin-treated spheroids exhibited less p-Akt
associated membrane staining but increased diffuse
staining in the cytoplasm. Similar results were observed
in doxorubicin-treated RL95-2 cell aggregates. Cisplatin
did not induce obvious changes. On the other hand, cell
clusters of KLE cells showed weak staining of p-Akt.
Western blotting showed that spheroids of Ishikawa
cells expressed p-Akt, which was not altered by antican-
cer drugs (Figure 8B-a). Cell monolayers of Ishikawa
cells had low expression of p-Akt (Figure 8B-c) and
doxorubicin slightly increased p-Akt expression (Figure
8B-c). Cell aggregates of RL95-2 cell line (Figure 8B-e)
expressed p-Akt, which was not altered by anticancer
drugs. Interestingly, cell monolayers of RL95-2 cell line
had no detectable levels of p-Akt (Figure 8B-g) even
though there were substantial levels of total Akt (Figure
8B-h). Neither cell aggregates nor cell monolayers of
KLE expressed detectable p-Akt.
The results are consistent with the notion that the
constitutive expression of p-Akt may enhance resistance
to doxorubicin and cisplatin in 3D multicellular struc-
tures of Ishikawa and RL95-2 cells.
Discussion
The microenvironment of multicellular structures regu-
lates gene and protein expressions, which are distinct
from those in cell monolayer counterparts [10,19]. How-
ever, the use of multicellular structures in investigations
of responses to drugs is novel and not widespread, and
never previously studied in endometrial cancer. Thus,
there is a gap in data as it pertains to the study of endo-
metrial cancer. To the best of our knowledge, this is the
first study on the use of multicellular structures in
endometrial cancer and it further investigates the antitu-
mour potential of clinical drugs. We have considered
the potential of cell responses in an in vitro 3D cell
model to provide useful prognostic biomarkers that may
have beneficial clinical relevance.
In our conditions, distinct multicellular morphologies
of cancer cell lines were observed as compact spheroids
(Ishikawa cell line), cell aggregates (RL95-2 cell line),
and cell clusters (KLE cell line). The exact mechanism,
which may influence the spheroid formation, is still
poorly defined but there are few studies that note the
potential relationships of individual cancer phenotypes,
production of extracellular matrix (ECM) and the
expression of integrin subunits. For instance, the forma-
tion of compact spheroids in ovarian cancer cells may
be associated with production of ECM, displaying a
mesenchymal phenotype, and influence the invasive
behaviour of cancer cell lines [20]. Small quantity of
basement membrane extract (Matrigel) added to cell
aggregations can stimulate cell aggregates to form com-
pact spheroids [21], thereby suggesting the contribution
of ECM in the early stage of compact spheroids forma-
tion. Possibly promotion of rapid cell aggregation is
induced by integrin-ECM in the initial stage of spheroid
assembly [12,22]. The development from loose
Figure 8 Expression of Akt and p-Akt.( A )E f f e c t so n
immunohistochemistry staining of p-Akt by doxorubicin and
cisplatin. Multicellular structures of Ishikawa, RL95-2 and KLE cells
were cut, fixed and stained with anti-p-Akt antibody. p-Akt was
stained green and the nucleus is blue. The scale bar is 50 μm. (B)
Western blotting of active form Akt (p-Akt) and total expression of
Akt. After 48 hours treatment with anticancer drugs, cells were lysed
and proteins were separated and analysed by SDS-PAGE and
Western blotting. The active form (p-Akt) and total expression of Akt
of multicellular structures of Ishikawa (B:a-b,), RL95-2 (B:e-f), KLE (B:i-j)
and cell monolayers of Ishikawa (B:c-d), RL95-2 (B:g-h), KLE (B:k-l).
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on cell adhesion protein, E-cadherin [22]. Cell lines used
in our investigations express measurable levels of b1
integrin subunit and Ecadherin [23-25]. Therefore, these
adhesion molecules may be not directly involved in the
early steps of spheroid formation. It is possible that
these cell lines may produce various degrees of ECM,
which may facilitate the initial cell-cell and cell-ECM
interactions that generate compact spheroids. In the
present study, we did not investigate the molecular nat-
ure of the ECM within spheroids and it remains to be
determined in the conditions of the current study.
Cell aggregates and clusters derived from RL95-2 and
KLE cell lines respectively, contained fewer apoptotic
cells after doxorubicin treatment compared to their cell
monolayers. However, apoptosis was also increased in
Ishikawa cells but there was no difference between
spheroids and cell monolayers. This led us to speculate
that the compactness of spheroids in Ishikawa cells
plays only a minor role in protection of cells from apop-
tosis after doxorubicin treatment. We had confirmed
diffusion of fluorescent doxorubicin to the central
region of spheroids, indicating that the limitation of
drug accessibility was not responsible for insensitivity to
doxorubicin in this study, although spheroids greater
than 250 μm in diameters may have reduced doxorubi-
cin penetration [15].
The mutation of TP53 tumour suppressor gene is
common in endometrial cancer. Cancer cells carrying
wild-type p53 protein can exert a variety of anti-prolif-
erative effects, including induction of apoptosis [26].
Accordingly, loss of wild-type p53 functions could lead
to increased chemoresistance. Endometrial cancer cell
lines used in our study all have TP53 gene alterations;
deletion in RL95-2, and mutations in KLE and Ishikawa
[27,28] cell lines. However, the sensitivity to doxorubicin
was markedly different between 3D multicellular struc-
tures and cell monolayers of RL95-2 and KLE cell lines.
Our observations may suggest that expression and func-
tionality of p53 protein may be distinct in 3D cultures
compared to cell monolayers.
There are many possible explanations for multicellular
structures showing greater resistance to doxorubicin
than cell monolayers. One possibility is that a number
of cancer cells at the central core of spheroids are in a
quiescent state, in which DNA topoisomerase II levels
are low. As a consequence, the number of doxorubicin-
induced DNA strand breaks is lower than in fast grow-
ing cells [6]. This is consistent with our data showing
that PCNA containing cells in RL95-2 cell aggregates
were observed at core regions and they were more sen-
sitive to doxorubicin than Ishikawa spheroids. Second,
spheroid formation is a process, in which cancer cells
survive by anchorage independent pathways that is a
hallmark of cancer metastasis. Data suggests survival
and resistance to anticancer drugs by anchorage-inde-
pendent pathways are sustained by an activation of
growth factor related signalling pathways [29], which are
differently modulated in the distinct microenvironments.
It is interesting that cisplatin did not induce apoptosis
or necrosis in our present study. Others have shown
that cisplatin reduced cell proliferation and increased
apoptosis in cell monolayers of Ishikawa and KLE cell
lines. These discrepancies may be due to the use of dif-
ferent techniques to analyse effects of the drug [30].
The difference of activity of doxorubicin and cisplatin
in inducing apoptosis in 3D multicellular structures and
cell monolayers led us to investigate cell proliferation.
Cell proliferation of Ishikawa spheroids was unchanged
after doxorubicin treatment. Surprisingly, more prolif-
erative cells were observed in the central region after
treatment. This demonstrated that different cell popula-
tion became proliferative in different regions of spher-
oids. These observations indicate that there is a
heterogeneous cell population in spheroids [31]. It is
also possible that spheroids after drug-treatment may
have altered cell-cell interaction at the rim, which
enabled increased penetration of nutrition to the inner
regions of spheroids, thereby initiating cell proliferation
of quiescent cells [11,32]. This phenomenon has been
reported in tumours of patients after they received che-
motherapy-radiation [33,34], which suggests the 3D
model may provide interactions that induce cancer cells
to behave similarly to an in vivo environment.
Cell proliferation appears to be linked with p-Erk1/2
[35]. The association of increased expression of p-Erk
with acquisition of spheroid resistance to chemothera-
peutic drugs supported this idea. Both cell aggregates
and monolayers of RL95-2 cells reduced p-Erk after
doxorubicin treatment and subsequently decreased cell
proliferation. However, the reduction of p-Erk in spher-
oids of Ishikawa cells did not parallel proliferation,
which was unaffected by the treatment. Therefore, Erk
in compact spheroids of Ishikawa cells and cell aggrega-
tions of RL95-2 cells may activate distinct pathways to
regulate cell proliferation. In contrast to Ishikawa and
RL95-2 cells, cell clusters of KLE treated with doxorubi-
cin did not exhibit reduced p-Erk and cell proliferation.
Taken together, this may suggest that each cell line has
various pathways to regulate cell proliferation and that
such pathways may be adapted to the microenviron-
ments of tumours.
The results also showed there was lack of correlation
of glucose metabolism in cell proliferation with apopto-
tic events after drug treatments, supporting previous
observations [36]. Doxorubicin increased glucose meta-
bolism in Ishikawa cell spheroids and RL-952 cell aggre-
gates but it decreased glucose metabolism in KLE cell
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lism in RL-952 and KLE 3D cell cultures. The results
may suggest the distinct responses of glucose metabo-
lism to anticancer agents depending on cancer cell lines.
In our study, staining of Glut-1 was observed at the
plasma membrane of cells and was also adjacent to the
core of the spheroids. Strikingly, after treatment with
doxorubicin, the staining of Glut-1 was mainly in the
central region and was localised in the cytoplasm of
cells. The reduction of Glut-1 staining, however, did not
correlate with the increase of glucose metabolism with
doxorubicin treatment. Furthermore, it was surprising
that cell monolayers of Ishikawa and RL95-2 cell lines
did not alter the uptake of 2-NBDG after treatment.
Also, it is noted that doxorubicin and cisplatin have dif-
ferent effects on the uptake of 2-NBDG, which may sug-
gest that drugs have specific targets that are distinct in
each cancer cell line. It is possible that many Gluts,
besides Glut-1, may be responsible for the uptake of 2-
NBDG [37]. Alternatively, the activity of Glut-1 rather
than the expression of protein may be responsible for
the increase of uptake 2-NBDG.
The observed resistance to anticancer drugs could also
be due to upregulation of endogenous antioxidant pro-
teins. Doxorubicin and cisplatin have been shown to
increase ROS, which is believed to be the primary
mechanism contributing to the induction of apoptosis in
cancer cells [38,39]. Our findings suggest that SOD-1,
which is localised mainly in the cytoplasm of cancer
cells, may protect cells from cytotoxic insult. However,
it seems likely that multicellular structures produce a
high level of SOD-1 compared with the cell monolayers,
in agreement with others [40,41]. This led us to specu-
late that nutrient depletion in the 3D multicellular mor-
phology may generate cellular metabolic stresses, which
in turn increase the production of endogenous antioxi-
dant molecules in a homeostatic response. Thus, the
microenvironment within multicellular structures can
significantly impact on the success of chemotherapeutic
treatments.
It is well known that secretion of VEGF is strongly sti-
mulated by tumour hypoxia. Increase of HIF-1a expres-
sion in a 3D spheroid has been demonstrated [42,43].
However, there are many inconsistent data regarding
the association VEGF and hypoxic microenvironment in
the 3D spheroid. VEGF localisation was strongly
observed in the outer cell layers that were directly
exposed to the growth medium in spite of having the
low oxygen level in the core of spheroids [14]. Increased
secretion of VEGF is evidenced in colorectal cancer
spheroids but this is not affected by hypoxia [16]. The
relatively short culture period in our experiments (5
days) and small size of multicellular morphology could
however explain the difference from independent
reports. In our study, multicellular structures produced
less VEGF compared to cell monolayers. This finding
may suggest that there are other factors in addition to
the influence of hypoxia that can contribute to elevated
levels of VEGF production and secretion. Interestingly,
doxorubicin and cisplatin had no reductive effects on
VEGF secretion in multicellular structures but instead
exhibited selective stimulatory effects. This has impor-
tant clinical implications in that the angiogenic and
growth enhancing activities of VEGF are paradoxically
encouraged by the putative anticancer drugs in 3D tis-
sue microenvironments. The current finding may sug-
gest that the effects of anticancer agents on VEGF
activity may be as a result of the different molecular
pathways according to individual characteristics of the
tumours [14,44].
The immunostaining showed that spheroids of Ishi-
kawa and cell aggregates of RL95-2 cells constitutively
expressed p-Akt. It is known that Ishikawa and RL95-2
cells harbour PTEN mutated inactive protein [45], and
that leads to the upregulation of the Akt signalling path-
way. Nevertheless, there was less p-Akt expressed in cell
monolayers than spheroids. Therefore, our data may
suggest that microenvironments within spheroids, such
as EGFR-related pathways [46], are able to produce
intracellular cues to trigger and sustain p-Akt activation.
Interestingly, p-Akt in cell monolayers of Ishikawa was
up-regulated after exposure to doxorubicin. This result
implies that increased p-Akt levels are a potential defen-
sive mechanism [47]. Some differences between spher-
oids and monolayers have been ascribed to PI3K/Akt/
mTOR activities [48]. Further, our results also revealed
that KLE cells did not have readily detectable p-Akt
staining, consistent with previous reports that grade 3
tumours had wild type PTEN [49] and low levels of p-
Akt [30]. Therefore, the resistance to doxorubicin in cell
clusters of KLE may be modulated by Akt independent
pathways. Alternatively, constitutive activation may be
reduced in cell monolayers and less compact spheroids
[50,51] as it noted in KLE cell line.
We report the pathways that are altered by anti-can-
cer drugs in a 3D multicellular structure are dependent
on oncogenic genotype, thus adding to the burgeoning
literature that cautions against ignoring individual
responsiveness in clinical situations. This study under-
took a comparison between characteristics of cancer
cells in monolayers and 3D multicellular structures
and thereby providing direct evidence of the influence
of the cellular microenvironment. For the first time
such information is available for endometrial cancer.
In this study, there appears to be no significant effects
in cisplatin-treated spheroids. Of particular note was
the observation that anti-cancer drugs might increase
VEGF secretion.
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Our investigations demonstrated that there were varia-
tions in metabolic activities, growth pattern, response to
chemotherapy among cancer cell lines, and cell culture
methods. In general, the intracellular mediators in 3D
multicellular morphologies demonstrated greater resis-
tance to chemotherapy than in monolayers. These
observations have important implications with regard to
the in vitro study of anticancer treatments for endome-
trial cancer. In addition, a chemotherapeutic sensitivity
assay in a 3D cell model that supports culture of pri-
mary cancer cells from patients may offer a closer
approximation of clinical sensitivity than a monolayer
culture and may also enable the tailoring of individual
chemotherapy treatments in patients with advanced
endometrial cancer.
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